EXEL
$16.49
Exelixis
($.04)
(.24%)
EXEL
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  $0.13
Revenue:  $231.61 Mil
Wednesday
Jan 29
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when EXEL reports earnings?
Beat
Meet
Miss

Where is EXEL's stock price going from here?
Up
Flat
Down
Stock chart of EXEL
Analysts
Summary of analysts' recommendations for EXEL
Score
Grade
Pivots
Resistance
$17.11
$16.91
$16.72

$16.52

Support
$16.33
$16.13
$15.94
Tweet
Growth
Description
Exelixis Inc. is a leader in the fields of model system genetics and comparative genomics. These fields involve the systematic study of simple organisms, such as fruit flies, nematodes, mice, zebrafish and simple plants, to rapidly and efficiently determine gene function and establish its commercial utility in humans and other commercially important biological systems. The proprietary technologies provide a rapid, efficient and cost-effective way to move beyond DNA sequence data to understand the function of genes and the proteins that they encode.
Peers
Alexion PharmaceuticalsIncyteExact SciencesCharles River Laboratories InternationalCoherus BiosciencesLuminex